5-(4-硝基苯基)-4H-1,2,4-三唑-3-胺 | 59301-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(4-硝基苯基)-4H-1,2,4-三唑-3-胺
• 英文名称: 3-(4-nitrophenyl)-1H-1,2,4-triazol-5-amine
• 英文别名: 5-(4-nitro-phenyl)-1H-[1,2,4]triazol-3-ylamine；5-(4-nitrophenyl)-1H-1,2,4-triazol-3-amine
• CAS: 59301-21-2
• 化学式: C₈H₇N₅O₂
• 分子量: 205.176
• InChiKey: VNQHSLZBEBYZHO-UHFFFAOYSA-N

物化性质

• 熔点：
  270 °C
• 沸点：
  514.0±52.0 °C(Predicted)
• 密度：
  1.535

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(4-硝基苯基)-4H-1,2,4-三唑-3-胺 在 palladium on activated charcoal 甲醇 作用下， 生成 5-(4-aminophenyl)-1H-1,2,4-triazol-3-amine
  参考文献：
  名称：

  Synthesis and Pharmacological Activity of Triazole Derivatives Inhibiting Eosinophilia

  摘要：

  In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1-[(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the ah-way through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1-[(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally tip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD(50) value of > 2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D-4 (LTD(4)) or platelet-activating factor (PAF)-induced responses. Taken together, these results suggest 23e as a novel candidate for the treatment of chronic asthma. Further studies are now underway.

  DOI：

  10.1021/jm9507993
• 作为产物：
  描述：

  4-Nitrobenzoic acid 2-amidinohydrazide 以 水 为溶剂， 反应 0.2h， 以45%的产率得到5-(4-硝基苯基)-4H-1,2,4-三唑-3-胺
  参考文献：
  名称：

  作为抗微管剂的3-芳基/杂芳基-5-氨基-1-（3'，4'，5'-三甲氧基苯甲酰基）-1,2,4-三唑。设计，合成，抗增殖活性和抑制微管蛋白聚合

  摘要：

  已知许多天然和合成物质会干扰微管蛋白的动态组装，从而阻止微管的形成。在我们寻找有效的和选择性的抗肿瘤剂中，合成了一系列新的1-（3'，4'，5'-三甲氧基苯甲酰基）-5-氨基-1,2,4-三唑。这些化合物具有不同的杂环，包括噻吩，呋喃或三个同分异构的吡啶，并且它们在5-氨基-1,2,4-三唑体系的3位上具有带电子释放或吸电子取代基的苯环。 。测试的22种化合物中的大多数对一组实体瘤和白血病细胞系均显示出中度至强效的抗增殖活性，其中4种（5j，5k，5o和5p） 对选定的癌细胞显示出强大的抗增殖活性（IC 50 <1μM）。其中，有几种分子优先抑制白血病细胞系的增殖，显示Jurkat和RS4; 11细胞的IC 50值比源自实体瘤的三系（HeLa，HT-29和MCF- 7个单元格）。化合物5k强烈抑制微管蛋白组装，IC 50值为0.66μM，是在CA-4的同时实验中获得的一半（IC 50  =

  DOI：

  10.1016/j.bioorg.2018.06.037

文献信息

• Microscale Parallel Synthesis of Acylated Aminotriazoles Enabling the Development of Factor XIIa and Thrombin Inhibitors
  作者：Simon Platte、Marvin Korff、Lukas Imberg、Ilker Balicioglu、Catharina Erbacher、Jonas M. Will、Constantin G. Daniliuc、Uwe Karst、Dmitrii V. Kalinin

  DOI：10.1002/cmdc.202100431

  日期：2021.12.14

  approach toward N-acylated aminotriazoles is reported, enabling the compounds’ screening against FXIIa and thrombin. This approach afforded low-nanomolar FXIIa and thrombin inhibitors with no off-targeting of the other tested serine proteases. Selected compounds were shown to be covalent inhibitors of FXIIa and demonstrated anticoagulant properties in vitro, influencing the intrinsic blood coagulation

  抗凝剂进展：报道了一种 N-酰化氨基三唑的微量平行合成方法，使该化合物能够针对 FXIIa 和凝血酶进行筛选。这种方法提供了低纳摩尔浓度的 FXIIa 和凝血酶抑制剂，且其他测试的丝氨酸蛋白酶没有脱靶。选定的化合物被证明是 FXIIa 的共价抑制剂，并在体外表现出抗凝血特性，影响内在的凝血途径。
• A green one-pot synthesis of 3(5)-substituted 1,2,4-triazol-5(3)-amines as potential antimicrobial agents
  作者：Hamid Beyzaei、Zahra Khosravi、Reza Aryan、Behzad Ghasemi

  DOI：10.1007/s13738-019-01714-2

  日期：2019.12

  The best antibacterial effects were observed with 3(5)-phenyl-1H-1,2,4-triazol-5(3)-amine according to its MIC values (4–8 μg mL−1). All compounds were successful in blocking the growth of fungi. Acceptable antioxidant properties were observed only with 3(5)-(4-nitrophenyl)-1H-1,2,4-triazol-5(3)-amine. Graphic abstract3(5)-Substituted 1,2,4-triazol-5(3)-amines were efficiently prepared via a one-pot

  摘要提出了一种通过硫脲，硫酸二甲酯和各种酰肼的一锅反应合成3（5）-取代的1,2,4-三唑-5（3）-胺的有效方法。1,2,4-三唑衍生物是在温和的条件下在水性介质中制备的，同时遵守一些绿色化学原理。无需任何进一步纯化即可轻松分离出产物，产率为83–95％。评估了所有合成化合物对各种革兰氏阳性和革兰氏阴性病原菌以及一些真菌病原体的抑制活性。根据其MIC值（4–8μgmL -1，使用3（5）-苯基-1 H -1,2,4-三唑-5（3）-胺观察到了最佳的抗菌作用）。所有化合物均能成功阻止真菌生长。仅使用3（5）-（4-硝基苯基）-1 H -1,2,4-三唑-5（3）-胺观察到可接受的抗氧化剂性能。 图形摘要通过硫脲，硫酸二甲酯和各种酰肼在水中作为溶剂的一锅反应，可有效地制备3（5）-取代的1,2,4-三唑-5（3）-胺。根据它们的MIC，MBC和MFC值证明了所有合成衍生物的抑制活性。发现它们是潜在的抗真菌剂。
• TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：THE GREEN CROSS CORPORATION

  公开号：EP0710654A1

  公开（公告）日：1996-05-08

  An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) or the following formula (III) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

  一种预防和治疗免疫相关疾病的制剂，特别是免疫抑制剂，一种预防和治疗过敏性疾病的制剂，一种预防和治疗嗜酸性粒细胞相关疾病的制剂和一种嗜酸性粒细胞增多抑制剂，其活性成分包括下式（I）的一系列三唑衍生物 或下式（III） 其中各符号如说明书中所定义，或其药学上可接受的盐。一种新型单环或双环三唑衍生物。本发明的预防和治疗免疫相关疾病的制剂，特别是免疫抑制剂、预防和治疗过敏性疾病的制剂、预防和治疗嗜酸性粒细胞相关疾病的制剂、嗜酸性粒细胞抑制剂和新型三唑衍生物都具有优异的嗜酸性粒细胞抑制作用和淋巴细胞活化抑制作用。它们毒性低，作用持久。它们对治疗嗜酸性粒细胞和淋巴细胞的积聚和活化、呼吸道炎症性疾病、嗜酸性粒细胞相关疾病（如嗜酸性粒细胞增多症）以及免疫相关疾病特别有效。
• Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold
  作者：Huseyin Istanbullu、Gunes Coban、Ezgi Turunc、Cagla Disel、Bilge Debelec Butuner

  DOI：10.1016/j.bioorg.2024.107430

  日期：2024.7

  of transcription (STAT) pathway mediates many cytokine and growth factor signals. Tyrosine kinase 2 (TYK2), one of the members of this pathway and the first described member of the JAK family. TYK2 associates with inflammatory and autoimmune diseases, cancer and diabetes. Here, we present novel compounds as selective inhibitors of the canonical kinase domain of TYK2 enzyme. These compounds were rationally

  Janus 激酶 (JAK) 信号转导和转录激活因子 (STAT) 途径介导许多细胞因子和生长因子信号。酪氨酸激酶 2 (TYK2)，该通路的成员之一，也是 JAK 家族中第一个被描述的成员。 TYK2 与炎症和自身免疫性疾病、癌症和糖尿病有关。在这里，我们提出了作为 TYK2 酶经典激酶结构域选择性抑制剂的新型化合物。这些化合物经过合理设计并通过适当的反应合成。使用分子建模技术来设计和优化 TYK2 抑制候选物，并确定它们在 JAK 内的估计结合方向。经测定确定，设计的化合物可有效抑制 TYK2，并对其他 JAK 具有良好的选择性。为了验证其选择性特性，针对 58 种人类激酶对化合物进行了测试（KinaseProfiler™ 测定）。在 THP-1 单核细胞中也检测到了选定的七种化合物对 JAK/STAT 家族成员的蛋白质水平的影响，尽管这些蛋白质的基础水平很难检测到。因此，它们的表达是通过脂多糖处理诱导的，并且发现化合物
• DE1073499
  申请人：——

  公开号：——

  公开（公告）日：——